UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers and clinical trials in ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.120979, Article 120979

Genge, Angela

2023

Volltextzugriff (PDF)

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

PloS one, 2022-06, Vol.17 (6), p.e0269154-e0269154

2022

Volltextzugriff (PDF)

A Road Map for Remote Digital Health Technology for Motor Neuron Disease

Journal of medical Internet research, 2021-09, Vol.23 (9), p.e28766-e28766

2021

Volltextzugriff (PDF)

Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study

NeuroImage clinical, 2020-01, Vol.28, p.102385-102385, Article 102385

2020

Volltextzugriff (PDF)

Clinical studies in amyotrophic lateral sclerosis

Current opinion in neurology, 2022-10, Vol.35 (5), p.686-692

2022

Volltextzugriff (PDF)

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

NeuroImage clinical, 2024-01, Vol.43, p.103633, Article 103633

2024

Volltextzugriff (PDF)

2997 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: interim analysis of RAISE-XT

BMJ neurology open, 2024-08, Vol.6 (Suppl 1), p.A13-A13

2024

Volltextzugriff (PDF)

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864241243186-17562864241243186

2024

Volltextzugriff (PDF)

Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study

Neurology. Genetics, 2021-12, Vol.7 (6), p.e623-e623

2021

Volltextzugriff (PDF)

Edaravone administration in pivotal clinical Study 19

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2019-04, Vol.20 (3-4), p.298-299

2019

Volltextzugriff (PDF)

Aesthetic Temporalities Today: Present, Presentness, Re-Presentation

1, 2020

Volltextzugriff (PDF)

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

The New England journal of medicine, 2022-09, Vol.387 (12), p.1099-1110

2022

Volltextzugriff (PDF)

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Art History and Fetishism Abroad: Global Shiftings in Media and Methods

1, 2014

Volltextzugriff (PDF)

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Chest, 2011-10, Vol.140 (4), p.687A-687A

2011

Volltextzugriff (PDF)

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

BMC musculoskeletal disorders, 2013-05, Vol.14 (S2), p.P1-P1, Article P1

Genge, Angela

2013

Volltextzugriff (PDF)

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Journal of the neurological sciences, 2023-12, Vol.455, p.121088, Article 121088

2023

Volltextzugriff (PDF)

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

How to break the news in amyotrophic lateral sclerosis/motor neuron disease: practical guidelines from experts

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2024-09, p.1-10

2024

Volltextzugriff (PDF)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.122737, Article 122737

2023

Volltextzugriff (PDF)

1 – 25 von 217

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieAmyotrophic Lateral Sclerosis

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(160)

Publikationsform

Buchkapitel
(121)
Artikel
(93)
Bücher
(2)
Reviews
(1)

Sprache

Englisch
(217)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(26)
Neurosciences & Neurology
(21)
Clinical Neurology
(19)
Amyotrophic Lateral Sclerosis
(17)
Arts & Humanities
(15)
History Of Art / Art & Design Styles
(7)
Social & Cultural History
(7)
Clinical Trials
(6)
Theory Of Art
(6)
Cultural Studies
(5)
Magnetic Resonance Imaging
(4)
Mri
(4)
Patients
(4)
Genetics
(3)
Myasthenia Gravis
(3)
Neuroimaging
(3)
Neurosciences
(3)
Original
(3)
Placebos
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

Biomarkers and clinical trials in ALS

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

A Road Map for Remote Digital Health Technology for Motor Neuron Disease

Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy

Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study

Clinical studies in amyotrophic lateral sclerosis

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

2997 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: interim analysis of RAISE-XT

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study

Edaravone administration in pivotal clinical Study 19

Aesthetic Temporalities Today: Present, Presentness, Re-Presentation

Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

Art History and Fetishism Abroad: Global Shiftings in Media and Methods

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

How to break the news in amyotrophic lateral sclerosis/motor neuron disease: practical guidelines from experts

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Aktive Filter

Suchergebnisse filtern